サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1792773

虚血性視神経ニューロパチー治療の世界市場

Ischemic Optic Neuropathy Treatment

出版日
ページ情報
英文 473 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
虚血性視神経ニューロパチー治療の世界市場
出版日: 2025年08月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 473 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

虚血性視神経ニューロパチー治療の世界市場は2030年までに2億3,140万米ドルに達する見込み

2024年に2億720万米ドルと推定される虚血性視神経ニューロパチー治療の世界市場は、2024～2030年の分析期間においてCAGR 1.9%で成長し、2030年には2億3,140万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである副腎皮質ステロイドは、CAGR 1.1％を記録し、分析期間終了時には8,050万米ドルに達すると予測されます。代謝拮抗薬セグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は5,650万米ドルと推定、中国はCAGR 3.6％で成長予測

米国の虚血性視神経ニューロパチー治療市場は、2024年には5,650万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4,290万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7％と1.3％と予測されています。欧州では、ドイツがCAGR約0.9%で成長すると予測されています。

世界の虚血性視神経ニューロパチー治療市場- 主要動向と促進要因まとめ

なぜ虚血性視神経症は世界の視力医療で関心が高まっているのか？

虚血性視神経症（ION）は、突然の視力低下の重大な要因として、特に高齢者集団や全身性血管疾患を持つ人々において、ますます認識されるようになっています。虚血性視神経症は、視神経への血流不足が原因で発症し、速やかに対処しなければ、しばしば不可逆的な視力障害を引き起こします。前部虚血性視神経症（AION）と後部虚血性視神経症（PION）の2つの病型があり、前部虚血性視神経症の方が一般的で、視神経の前部が侵されます。IONの発症率は、高血圧、糖尿病、高脂血症、閉塞性睡眠時無呼吸症候群の世界の増加に伴って上昇しています。さらに、多くの国々では人口統計学的な高齢化が進んでおり、動脈性および非動脈性のIONに罹患しやすい患者数が増加しています。その有病率にもかかわらず、この疾患は突然発症し、初期症状が微妙であるため、しばしば過小診断されます。治療が遅れると永続的な視力喪失につながりかねないため、早期発見と介入が急務となっています。患者の精神的・機能的負担は大きく、しばしば生活の質の急激な低下につながります。現在の治療選択肢はまだ限られており、しばしば一貫した結果が得られないため、診断ツールの改善、リスク軽減戦略、効果的な治療薬の必要性がかつてないほど高まっています。

虚血性視神経ニューロパチー治療の情勢はどのように変化しているか？

虚血性視神経症の治療法は、臨床医と研究者が薬理学的介入と非薬理学的介入の両方を模索し、視力の維持・回復を目指す中で徐々に変化しています。現在のところ、管理アプローチは亜型と基礎にある病因によって異なります。しばしば巨細胞性動脈炎を伴う動脈炎性AIONでは、高用量のコルチコステロイドが標準治療であり、両側の視力低下を防ぐために速やかに投与しなければならないです。しかし、より一般的な非動脈炎性AIONの場合、治療は主に支持療法と予防療法にとどまっています。急性期の視神経損傷を軽減するために、神経保護剤、抗酸化剤、抗炎症剤の使用に関心が高まっています。臨床試験では、ブリモニジン、シチコリンなど、ミトコンドリア機能の亢進と神経細胞アポトーシスの抑制を目的とした薬剤の有効性が検討されています。同時に、抗血小板薬や微小循環を改善する薬剤を含む血管を標的とした治療が、視神経灌流を維持する可能性について研究されています。低レベルの光治療や視神経の電気刺激は、実験的なプロトコールのもとで、非侵襲的な選択肢の可能性が出てきています。さらに、光干渉断層計（OCT）やフルオレセイン血管造影などの画像診断法の改良が、疾患の早期発見や進行のモニタリングに役立っています。この分野は、標準化された治療アルゴリズムの欠如と限られた質の高いエビデンスによって阻害され続けているが、治療ツールボックスを拡大するための集団的努力は、より積極的で個別化された治療戦略へのシフトを示唆しています。

リスク層別化と早期診断は治療成績をどのように形成しているか？

虚血性視神経症の治療では、リスク層別化と早期診断がますます重要になってきています。虚血性視神経症の多くの症例は慢性血管疾患、夜間低血圧、視神経小頭症などと関連しているため、全身および眼の危険因子を認識することは非常に重要です。画像診断の進歩により、IONを視神経炎や圧迫性病変などの他の視神経疾患と鑑別する臨床医の能力は向上しています。OCTや視野検査などのツールは、網膜神経線維の太さの微妙な変化や中心視野の欠損を検出するのに役立ち、現在では診断検査の標準的な要素となっています。さらに、血液検査と側頭動脈生検は、ステロイド投与が遅れると両眼失明に至る可能性のある動脈炎型の診断に極めて重要です。プライマリ・ケア提供者や眼科医は現在、特に高齢者、糖尿病患者、降圧剤服用者などのリスクのある集団において、イオンの徴候や症状を認識するための訓練を受けています。また、特に基礎疾患を持つ患者に対しては、血圧、グルコース値、脂質プロファイルを管理することの重要性を理解するよう、患者教育が重視されています。個別化されたリスク評価と集学的治療経路を取り入れることにより、臨床医は予防戦略を実施し、高リスク者をより綿密に監視することができます。早期発見と個別化された介入へのシフトは、臨床転帰を徐々に改善し、最終的には疾病発生率の低下につながる可能性があります。

虚血性視神経ニューロパチー治療市場の成長を促進する要因は？

虚血性視神経ニューロパチー治療市場の成長は、疫学動向、臨床革新、患者意識、技術進歩など、相互に関連するいくつかの要因によってもたらされます。世界人口の高齢化は、動脈硬化型および非動脈硬化型両方のイオンの主要な危険因子であるため、主要な促進要因となっています。糖尿病、高血圧、自己免疫疾患などの全身疾患が同時に増加しているため、特に都市部や中所得国では、リスクのある患者がさらに増加しています。画像診断の進歩により、より早期かつ正確な発見が可能になり、治療介入やモニタリングの拡大が促されています。医薬品の研究は、神経保護療法や血管治療の分野にも広がっており、疾患の急性期と慢性期に対する新規薬剤の有効性を評価する臨床試験が進行中です。患者アドボカシーや一般への啓蒙活動も、早期診断や、より多くの情報に基づいたヘルスケアに関する意思決定に寄与しています。さらに、遠隔医療と眼科遠隔診察の統合により、十分な医療を受けられない地域の専門医へのアクセスが向上し、潜在市場が拡大しています。病院や診療所は、患者の転帰を追跡して治療計画を調整するために、診断インフラや電子カルテに投資しています。臨床研究が進み、治療プロトコールがより洗練されるにつれて、疾病管理に対するより構造化されたデータ主導のアプローチから市場は恩恵を受けると思われます。こうした力学が総合的に、早期診断、標的治療、包括的なリスク管理に重点を置きながら、虚血性視神経ニューロパチー治療市場を着実な成長へと押し上げています。

セグメント

薬剤クラス（副腎皮質ステロイド薬、代謝拮抗薬、抗凝固薬、セロトニン・ノルエピネフリン再取り込み阻害薬、非ステロイド性抗炎症薬クラス）、投与経路（経口投与、注射投与）、疾患タイプ（後虚血性視神経症、前虚血性視神経症）、流通チャネル（病院薬局、小売薬局、ドラッグストア、オンライン流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Allergan（a part of AbbVie）
  • Amgen Inc.
  • Apellis Pharmaceuticals
  • Astellas Pharma Inc.
  • Bayer AG
  • Bausch+Lomb
  • Biogen Inc.
  • Bristol Myers Squibb
  • Clearside Biomedical
  • Genentech（Roche Group）
  • Glaukos Corporation
  • Ionis Pharmaceuticals
  • Johnson & Johnson Vision
  • Kiora Pharmaceuticals
  • Lineage Cell Therapeutics
  • Neurotech Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37214

Global Ischemic Optic Neuropathy Treatment Market to Reach US$231.4 Million by 2030

The global market for Ischemic Optic Neuropathy Treatment estimated at US$207.2 Million in the year 2024, is expected to reach US$231.4 Million by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 1.1% CAGR and reach US$80.5 Million by the end of the analysis period. Growth in the Antimetabolites segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$56.5 Million While China is Forecast to Grow at 3.6% CAGR

The Ischemic Optic Neuropathy Treatment market in the U.S. is estimated at US$56.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$42.9 Million by the year 2030 trailing a CAGR of 3.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Ischemic Optic Neuropathy Treatment Market - Key Trends & Drivers Summarized

Why Is Ischemic Optic Neuropathy a Growing Concern in Vision Health Worldwide?

Ischemic optic neuropathy (ION) is increasingly recognized as a critical contributor to sudden vision loss, particularly in aging populations and individuals with systemic vascular conditions. It results from insufficient blood flow to the optic nerve, often causing irreversible visual impairment if not promptly addressed. There are two main forms: anterior ischemic optic neuropathy (AION), which is more common and affects the front part of the optic nerve, and posterior ischemic optic neuropathy (PION), which is rarer and affects the back portion. The incidence of ION is rising in parallel with the global increase in hypertension, diabetes, hyperlipidemia, and obstructive sleep apnea-conditions that compromise vascular integrity and circulation. Moreover, the aging demographic profile in many countries is leading to higher numbers of patients vulnerable to both arteritic and non-arteritic forms of ION. Despite its prevalence, the condition often goes underdiagnosed due to its sudden onset and the subtlety of early symptoms. Delays in treatment can result in permanent vision loss, adding to the urgency of early detection and intervention. The emotional and functional burden on patients is significant, often leading to a sharp decline in quality of life. With current treatment options still limited and often yielding inconsistent results, the need for improved diagnostic tools, risk mitigation strategies, and effective therapeutics has never been more pressing.

How Is the Landscape of Ischemic Optic Neuropathy Treatment Evolving?

The treatment landscape for ischemic optic neuropathy is undergoing gradual transformation as clinicians and researchers explore both pharmacologic and non-pharmacologic interventions to preserve or restore vision. Currently, the management approach depends on the subtype and underlying etiology. In arteritic AION, often associated with giant cell arteritis, high-dose corticosteroids are the standard of care and must be administered promptly to prevent bilateral vision loss. However, for the more common non-arteritic form, which is not inflammatory, treatment remains largely supportive and preventative in nature. There is growing interest in the use of neuroprotective agents, antioxidants, and anti-inflammatory compounds to mitigate optic nerve damage during the acute phase. Clinical trials are exploring the efficacy of medications such as brimonidine, citicoline, and other agents aimed at enhancing mitochondrial function and reducing neuronal apoptosis. At the same time, vascular-targeted therapies including antiplatelet drugs and agents that improve microcirculation are being investigated for their potential to preserve optic nerve perfusion. Low-level light therapy and electrical stimulation of the optic nerve are emerging as potential non-invasive options under experimental protocols. Additionally, improved imaging modalities such as optical coherence tomography (OCT) and fluorescein angiography are aiding earlier detection and monitoring of disease progression. The field continues to be hampered by a lack of standardized treatment algorithms and limited high-quality evidence, but the collective effort to expand the therapeutic toolbox signals a shift toward more proactive and individualized care strategies.

How Are Risk Stratification and Early Diagnosis Shaping Treatment Outcomes?

Risk stratification and early diagnosis are becoming increasingly pivotal in the management of ischemic optic neuropathy, as timely intervention can often be the deciding factor between partial recovery and permanent vision loss. Recognizing systemic and ocular risk factors is critical, as many cases of ION are associated with chronic vascular diseases, nocturnal hypotension, and small optic nerve head anatomy. Advances in diagnostic imaging have improved clinicians’ ability to distinguish ION from other optic neuropathies such as optic neuritis or compressive lesions. Tools like OCT and visual field testing are now standard components of the diagnostic workup, helping detect subtle changes in retinal nerve fiber thickness and central field defects. Furthermore, blood tests and temporal artery biopsies are crucial for diagnosing arteritic forms of the disease, where delay in steroid administration can result in blindness in both eyes. Primary care providers and ophthalmologists are now increasingly trained to recognize the signs and symptoms of ION, particularly in at-risk populations, which include the elderly, diabetics, and those on antihypertensive medications. Patient education is also being emphasized, especially for individuals with underlying systemic conditions, so that they understand the importance of managing blood pressure, glucose levels, and lipid profiles. By incorporating personalized risk assessments and multidisciplinary care pathways, clinicians can implement preventive strategies and monitor high-risk individuals more closely. This shift toward early identification and tailored intervention is gradually improving clinical outcomes and may eventually lead to reduced disease incidence.

What Factors Are Driving the Growth of the Ischemic Optic Neuropathy Treatment Market?

The growth in the ischemic optic neuropathy treatment market is driven by several interrelated factors spanning epidemiological trends, clinical innovation, patient awareness, and technological progress. The aging global population is a primary driver, as advanced age is a leading risk factor for both arteritic and non-arteritic forms of ION. The concurrent rise in systemic diseases such as diabetes, hypertension, and autoimmune conditions is further increasing the pool of at-risk patients, particularly in urbanized and middle-income countries. Advances in diagnostic imaging are enabling earlier and more accurate detection, which is prompting greater therapeutic intervention and monitoring. Pharmaceutical research is expanding into neuroprotective and vascular therapies, with clinical trials underway to evaluate the efficacy of novel agents for acute and chronic phases of the disease. Patient advocacy and public awareness campaigns are also contributing to earlier presentation and more informed healthcare decisions. Additionally, the integration of telemedicine and remote ophthalmology consultations is enhancing access to specialist care in underserved regions, thereby broadening the potential market. Hospitals and clinics are investing in diagnostic infrastructure and electronic health records to track patient outcomes and tailor treatment plans. As clinical research progresses and treatment protocols become more refined, the market is likely to benefit from a more structured and data-driven approach to disease management. These dynamics are collectively propelling the ischemic optic neuropathy treatment market toward steady growth, with an emphasis on early diagnosis, targeted therapy, and comprehensive risk management.

SCOPE OF STUDY:

The report analyzes the Ischemic Optic Neuropathy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors, Nonsteroidal Anti-Inflammatory Drugs Class); Administration Route (Oral Administration, Injectable Administration); Disease Type (Posterior Ischemic Optic Neuropathy, Anterior Ischemic Optic Neuropathy); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Allergan (a part of AbbVie)
  • Amgen Inc.
  • Apellis Pharmaceuticals
  • Astellas Pharma Inc.
  • Bayer AG
  • Bausch + Lomb
  • Biogen Inc.
  • Bristol Myers Squibb
  • Clearside Biomedical
  • Genentech (Roche Group)
  • Glaukos Corporation
  • Ionis Pharmaceuticals
  • Johnson & Johnson Vision
  • Kiora Pharmaceuticals
  • Lineage Cell Therapeutics
  • Neurotech Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Ischemic Optic Neuropathy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Vision-Threatening Vascular Disorders Throws the Spotlight on Ischemic Optic Neuropathy as a Critical Unmet Clinical Need
    • Growing Awareness Among Ophthalmologists and Neurologists Propels Early Diagnosis and Intervention for ION
    • Here's the Story: Lack of Approved Therapeutics Strengthens the Business Case for Drug Development in ION Treatment Pipelines
    • Advances in Optical Coherence Tomography (OCT) and Imaging Tools Drive Accurate Detection and Disease Monitoring
    • Here's How Neuroprotective and Anti-Inflammatory Agents Are Emerging as Potential Front-Runners in ION Therapy Research
    • Expansion of Clinical Research in Rare Ophthalmic Disorders Fuels Interest in Novel Targets for Non-Arteritic and Arteritic ION
    • Increased Focus on Corticosteroid and Immunosuppressive Regimens Drives Debate Over Efficacy and Standard of Care
    • Here's How Gene Therapy and Regenerative Medicine Are Opening New Avenues for Vision Restoration in ION
    • Aging Population and Rising Cardiovascular Risk Factors Expand the Addressable Population for ION Therapies
    • Here's How Artificial Intelligence and Predictive Algorithms Are Assisting in Early Risk Stratification and Personalized Treatment
    • Challenges in Differential Diagnosis and Subtype Classification Drive Demand for Biomarkers and Standardized Criteria
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ischemic Optic Neuropathy Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ischemic Optic Neuropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antimetabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Serotonin & Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Serotonin & Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Serotonin & Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-Inflammatory Drugs Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Nonsteroidal Anti-Inflammatory Drugs Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Nonsteroidal Anti-Inflammatory Drugs Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Posterior Ischemic Optic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Posterior Ischemic Optic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Posterior Ischemic Optic Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Anterior Ischemic Optic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Anterior Ischemic Optic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Anterior Ischemic Optic Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • JAPAN
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • CHINA
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • EUROPE
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Ischemic Optic Neuropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • FRANCE
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: France 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • GERMANY
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Italy 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: UK 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: UK 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Spain 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Spain 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Russia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Russia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Australia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Australia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • INDIA
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: India 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: India 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: India 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: South Korea 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: South Korea 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Argentina 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Argentina 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Brazil 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Brazil 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Mexico 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Mexico 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 319: Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 322: Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 334: Iran 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 337: Iran 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 346: Israel 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 349: Israel 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 370: UAE 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 373: UAE 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030
  • AFRICA
    • Ischemic Optic Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Ischemic Optic Neuropathy Treatment by Drug Class - Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 394: Africa 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Antimetabolites, Anticoagulants, Serotonin & Norepinephrine Reuptake Inhibitors and Nonsteroidal Anti-Inflammatory Drugs Class for the Years 2014, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Ischemic Optic Neuropathy Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 397: Africa 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Ischemic Optic Neuropathy Treatment by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Ischemic Optic Neuropathy Treatment by Disease Type - Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for Ischemic Optic Neuropathy Treatment by Disease Type - Percentage Breakdown of Value Sales for Posterior Ischemic Optic Neuropathy and Anterior Ischemic Optic Neuropathy for the Years 2014, 2025 & 2030

IV. COMPETITION